课题基金 / 基金详情

ROLE OF TYPE-I IFN'S IN ANTIVIRAL CD8 CELL RESPONSE

ROLE OF TYPE-I IFN'S IN ANTIVIRAL CD8 CELL RESPONSE
I 型干扰素在抗病毒 CD8 细胞反应中的作用
批准号:
6690369
负责人:
MURALI KRISHNA KAJA
金额:
$30.32万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-12-15 至 2007-11-30

项目摘要

项目成果

MURALI KRISHNA KAJA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):我们研究的长期目标是了解急性病毒感染引发有效免疫反应的机制,希望从感染模型中获得的知识可以应用于改进疫苗接种策略。我们以前的研究,使用淋巴细胞性脉络膜脑膜炎病毒(LCMV)感染的小鼠模型,证明了急性病毒感染诱导的初级和记忆性CD8 T细胞反应比之前认为的要高得多。我们发现,即使在没有T细胞受体-MHC I类相互作用的情况下,这些抗病毒记忆CD8细胞也会持续很长一段时间。现在越来越清楚的是,即使在没有共刺激分子或专业的APC帮助的情况下,一些感染也可以引发显著的T细胞反应。其潜在机制尚不清楚。为了更好地了解这些机制,我们开始描述可能有助于病毒感染中T细胞反应增强的可能事件。我们发现,感染诱导的I型干扰素(干扰素α/β)(A)有助于增强CD8T细胞的反应,(B)在感染后早期导致初始T细胞的瞬时激活。我们推测,这种干扰素α/β介导的初始CD8T细胞增敏可能提供了一个额外的信号,增强了对抗原的应答能力。因此,即使在没有共刺激和或专业APC帮助的情况下,幼稚的CD8T细胞在感染条件下也可能反应良好。这一建议旨在通过以下假设来验证这一点:(1)初始CD8T细胞在感染诱导的干扰素α/β致敏后,可以降低其激活阈值,并对同种抗原刺激做出更好的反应;(2)在病毒感染过程中,干扰素α/β受体阳性(IFNR?/?/)CD8T细胞在激发免疫反应方面可能比受体阴性(IFNRα/β-/-)CD8T细胞具有选择性优势,以及,(3)在抗病毒应答过程中,与IFNRα/β/-CD8 T细胞相比,IFNRα/β/CD8 T细胞对专业APC帮助的依赖程度可能更低。这些研究将深入了解病毒感染中旁观者T细胞激活的生物学后果,以及先天免疫和获得性免疫之间的相互作用机制。这项工作对改进疫苗接种策略具有重要意义,并为未来的研究奠定了基础,这些研究旨在了解免疫记忆产生的机制,并对人类和动物健康具有重要意义。
英文摘要
DESCRIPTION (provided by applicant): The long-term objectives of our research are to understand the mechanisms by which acute viral infections induce potent immune responses with a hope that the knowledge gained from infectious models can be applied for improving vaccination strategies. Our previous studies, using mouse models of lymphocytic choriomeningitis virus (LCMV) infection, demonstrated that acute viral infections induce a much higher magnitude of primary and memory CD8 T cell responses than was previously thought. We found that these anti-viral memory CD8 cells persist for extended periods even in the absence of T cell receptor-MHC class I interactions. Now it is becoming clear that some infections can elicit significant T cell responses even in the absence of costimulatory molecules or professional APC help. The underlying mechanisms are not clear. To better understand these mechanisms, we started characterizing possible events that may contribute to the enhanced T cell response in viral infection. We found that infection-induced type-I interferons (IFN alpha/beta) (a) helps potentiate the CD8 T cell response and (b) cause a transient activation of naive T cells early after infection. We hypothesize that this IFN alpha/beta mediated sensitization of naive CD8 T cells may provide an additional signal that potentiates the ability to respond to antigen. As a result, the naive CD8 T cells may respond well even in the absence of co-stimulatory and or professional APC help under the conditions of infection. This proposal is aimed at testing this by pursuing the following hypotheses: (1) that naive CD8 T cells, upon sensitization by infection-induced IFN alpha/beta may lower their activation threshold and respond better to cognate antigenic stimulus, (2) that IFN alpha/beta receptor positive (IFNR ?/? +/+) CD8 T cells may have a selective advantage over receptor negative (IFNR alpha/beta -/-) CD8 T cells in eliciting immune response during viral infection, and, (3) that IFNR alpha/beta +/+ CD8 T cells may become less dependent upon professional APC help than IFNR alpha/beta -/- CD8 T cells during an anti-viral response. These studies will provide insight into the biological consequences of bystander T cell activation in viral infections and the mechanisms of cross-talk between innate and adaptive immunity. This work has implications for improving vaccination strategies and provides groundwork for future studies aimed at understanding the mechanisms involved in generation of immune memory and have significance for human and animal health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Vaccination Strategies Against Epidemic and Pandemic Influenza Viruses to I
  • 批准号:
    8318807
  • 项目类别:
  • 资助金额:
    $38.36万
  • 财政年份:
    2011
  • 负责人:
    MURALI KRISHNA KAJA
  • 依托单位:
Novel Vaccination Strategies Against Epidemic and Pandemic Influenza Viruses to I
  • 批准号:
    8227808
  • 项目类别:
  • 资助金额:
    $38.36万
  • 财政年份:
    2011
  • 负责人:
    MURALI KRISHNA KAJA
  • 依托单位:
Novel Vaccination Strategies Against Epidemic and Pandemic Influenza Viruses to I
  • 批准号:
    7924111
  • 项目类别:
  • 资助金额:
    $39.0万
  • 财政年份:
    2009
  • 负责人:
    MURALI KRISHNA KAJA
  • 依托单位:
IFN actions and immune cell activation by West Nile Virus
  • 批准号:
    7746285
  • 项目类别:
  • 资助金额:
    $31.7万
  • 财政年份:
    2009
  • 负责人:
    MURALI KRISHNA KAJA
  • 依托单位:
国内基金
海外基金
铋基邻近双金属位点Type B异质结光热催化合成氨机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2024
  • 负责人:
    黎景卫
  • 依托单位:
智能型Type-I光敏分子构效设计及其抗耐药性感染研究
  • 批准号:
    22207024
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    20.0万元
  • 批准年份:
    2022
  • 负责人:
    赵琦
  • 依托单位:
TypeⅠR-M系统在碳青霉烯耐药肺炎克雷伯菌流行中的作用机制研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    55万元
  • 批准年份:
    2021
  • 负责人:
    蒋晓飞
  • 依托单位:
替加环素耐药基因 tet(A) type 1 变异体在碳青霉烯耐药肺炎克雷伯菌中的流行、进化和传播
  • 批准号:
    LY22H200001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    蔡加昌
  • 依托单位: